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Tumor necrosis factor- (TNF-) is a pleiotropic pro-
inflammatory cytokine that modulates a broad range of
inflammatory and immunological processes. We have
investigated the potential immunomodulatory properties
of prostaglandin E2 (PGE2) by examining the molecular
mechanism by which the eicosanoid suppresses T-cell-de-
rived interleukin-17 (IL-17)-induced TNF- mRNA expres-
sion and protein synthesis in human macrophages and
rheumatoid arthritis-affected synovial fibroblasts. Initial
studies confirmed that PGE2 induces egr-1 mRNA expres-
sion and protein synthesis by restricted SAPK2/p38MAPK-
dependent activating transcription factor-2 (ATF-2) dimer
transactivation of the egr-1 promoter as judged by studies
using wild-type (WT) and deletion mutant egr-1 promoter
constructs, Northern and Western blotting, and standard
and supershift electrophoretic mobility shift analyses. Us-
ing human leukemic monocytic THP-1 cells stably trans-
fected with WT and dominant-negative mutant expression
constructs of Egr-1, cotransfected or not with a WT
pTNF615SVOCAT construct, we observed that PGE2 inhi-
bition of IL-17-stimulated TNF- mRNA expression and
promoter activity was dependent on Egr-1 expression, as
mutants of Egr-1, alone or in combination, markedly abro-
gated any inhibitory effect of PGE2. Standard and super-
shift electrophoretic mobility shift analysis, signaling
“decoy” overexpression studies, and pTNF615SVOCAT
promoter assaysusingWTandmutantpromoter constructs
revealed that IL-17-up-regulated promoter activity was
largely dependent on ATF-2/c-Jun transactivation. PGE2
suppression of IL-17-induced ATF-2/c-Jun transactivation
andDNAbindingwas dependent onEgr-1-mediated inhibi-
tionof inducedc-Junexpression.Wesuggest that egr-1 is an
immediate-early PGE2 target gene that may be a key regu-
latory factor in mediating eicosanoid control of genes in-
volved in the immune and inflammatory responses.
Inflammation and the inflammatory response represent a
highly orchestrated cascade of events designed to maintain a
state of homeostasis in the host following pathogenic invasion
and/or tissue injury. The response involves the concerted and
exquisitely timed interactions of cytokines, chemokines,
growth factors, and lipid-derived mediators with inflammatory
cells like macrophages, neutrophils, activated endothelial cells
and fibroblasts, T- and -lymphocytes, and mast cells (1–4).
Among the most important classes of lipid-derived mediators in
this regard are the prostaglandins of the E series that function
as pleiotropic autacoids and exert modulatory effects on the
immune and inflammatory responses in addition to acting as
essential physiological regulators in virtually every tissue of
the human organism (5, 6).
Prostaglandin E2 (PGE2)
1 is synthesized from the essential
fatty acid arachidonic acid by the enzymes of the arachidonate
cascade or, occasionally, by free radical-catalyzed peroxidation
(7). Upon cellular activation, type IV cytosolic phospholipase A2
translocates to the endoplasmic reticulum or outer nuclear
membrane and releases arachidonic acid from the membrane
lipids of most cell types (7, 8). The latter protein trafficking
event is controlled by calcium fluxes and MAPK phosphoryla-
tion of cytosolic phospholipase A2 (8). A co-localized, monotopic,
integral membrane protein, prostaglandin H2 synthase (also
referred to as cyclooxygenase (COX), with two isoforms, COX-1
and COX-2), catalyzes the first committed, rate-limiting step
by converting arachidonic acid to prostaglandin H2. The latter
intermediate is rapidly metabolized by cell- and tissue-specific
synthases to one of several prostanoids (e.g. PGE2 by prosta-
glandin E synthase) (9, 10).
The PGE2 signal is transduced at the cell surface by specific
cognate receptors (designated EP receptors, subtypes EP1–
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EP4) that are characterized by an extracellular N-terminal
domain, seven membrane-spanning regions containing a vari-
able cytoplasmic loop, and a cytoplasmic C terminus. Ligand
binding takes place in the membrane-spanning domains, and
G-protein coupling occurs through the intracellular loops and C
terminus (11–13). In general, EP2 and EP4 signal through Gs
coupling, resulting in increases in cAMP levels and activated
protein kinase A within seconds to minutes. The EP1 and some
EP3 receptor subtypes associate with Gq and mediate increases
in intracellular calcium, whereas Gi proteins reduce levels of
cellular cAMP (EP3) (8, 11). For example, the C terminus of EP
receptors also harbors serine/threonine residues (anywhere
from 1 to 9) that, when phosphorylated by activated protein
kinase A, induce receptor desensitization and signal attenua-
tion (reviewed in Ref. 13).
In a variety of target cell types, PGE2 modulates transcrip-
tion of immediate-early genes such as junB, junD, fosB, fra-1,
and c-fos, although the mechanistic details are completely un-
defined (14–16). These early gene products are transcription
factors that, along with CREB, ATF-1, ATF-2, and AP-2, mod-
ify the expression of PGE2 target genes (16, 17). The latter are
genes associated with mitogenic, apoptotic, hypertrophic, and
differentiation signals in many cell types, including stem cells
(18, 19). Signaling cascades mediating mitogenic activity such
as the Ras/Raf-1/ERK cascade are inhibited by PGE2 secondary
to phosphorylation and inactivation of Raf-1 kinase by protein
kinase A (20). In addition, the p38 MAPK cascade is a primary
target through which PGE2 signaling via EP4 is manifested in
human synovial fibroblasts and macrophages (21).
Preliminary data from this laboratory (23) and others (22,
24) suggest that a zinc finger transcription factor, the early
growth response gene egr-1/krox-24, may also be a target gene
of PGE2, although detailed studies regarding the mechanism of
egr-1/krox-24 gene induction and the specificity of cell-type
responsiveness were never performed. Also known as zif268,
egr-1/krox-24 was originally identified as a growth response
gene in fibroblasts and B-cells (25, 26). The expression of Egr-
1/Krox-24 is induced during differentiation of myeloid cells,
nerve, and bone and has been shown to be essential and deter-
minant for macrophage differentiation (reviewed in Ref. 26;
Refs. 27 and 28). It is a strong nuclear DNA-binding protein
that specifically recognizes the sequence 5-GCG(T/G)-
GGGCG-3 and can transactivate promoters containing the
appropriate cognate site. The promoters of tumor necrosis fac-
tor- (TNF-) (29), both chains of platelet-derived growth fac-
tor (30, 31), and transforming growth factor-1 (30) harbor
active binding/enhancer sites for Egr-1/Krox-24. Cell type de-
termines whether Egr-1/Krox-24 acts to activate or inhibit
promoter activity of target genes, suggesting that it interacts
with tissue-specific factors and/or transcription factors that
associate with proximal promoter elements such as Sp-1 (25,
31). In this study, we investigated in detail the regulatory
mechanisms controlling PGE2-dependent induction of the egr-1
gene in human monocytes/macrophages and rheumatoid ar-
thritis-transformed synovial cells. Our results indicate that
PGE2 induces Egr-1 expression through stimulation of the
MLK2/MKK3/p38 MAPK cascade with ATF-2 transactivation
of the egr-1 promoter. Furthermore, using dominant-negative
mutants in stably transfected cells lines, we show that PGE2
suppresses T-cell cytokine-induced TNF- gene expression and
synthesis in human macrophages (and rheumatoid arthritis
(RA)-affected synovial fibroblasts) largely through Egr-1-de-
pendent TNF- promoter suppression. The data suggest that
PGE2/Egr-1 disrupts essential components of the TNF- pro-
moter transactivation complex, viz. the suppression of ATF-2/
c-Jun heterodimer DNA binding through inhibition of c-Jun
expression.
MATERIALS AND METHODS
Chemicals—Sodium fluoride, leupeptin, aprotinin, pepstatin, phen-
ylmethylsulfonyl fluoride, actinomycin D, puromycin, dithiothreitol, so-
dium orthovanadate, and bovine serum albumin were products of
Sigma. PGE2, SB 202190, KT5720, phorbol 12-myristate 13-acetate
(PMA), ionomycin, A23187, forskolin, and rolipram were purchased
from Calbiochem. SDS, acrylamide, bisacrylamide, ammonium persul-
fate, and protein reagent were from Bio-Rad. Tris base, EDTA, MgCl2,
CaCl2, chloroform, Me2SO, anhydrous ethanol (95%), methanol (99%),
formaldehyde, and formamide were obtained from Fisher. Recombinant
human interleukin-17 (rhIL-17) was purchased from R&D Systems
(Minneapolis, MN). Dulbecco’s modified Eagle’s medium, phosphate-
free and phenol red-free Dulbecco’s modified Eagle’s medium, RPMI
1640 medium, TRIzol reagent, heat-inactivated fetal bovine serum, and
an antibiotic mixture (10,000 units of penicillin (base) and 10,000 g of
streptomycin (base)) were products of Invitrogen.
Cell Culture—Human peripheral blood mononuclear cells were iso-
lated from healthy donors by Ficoll-Hypaque density centrifugation
(Amersham Biosciences) as described previously (32), and the mono-
cytes/macrophages were allowed to adhere to plastic dishes (Flow Lab-
oratories, McLean, VA) in RPMI 1640 medium containing L-glutamine,
10% fetal calf serum (FCS), and penicillin/streptomycin (antibiotics).
THP-1 cells (2–3  106 cells/ml; American Type Culture Collection,
Manassas, VA), a human monocytic cell line, were cultured as suspen-
sions in RPMI 1640 medium supplemented with 50 M -mercaptoeth-
anol (23). Human RA-affected synovial fibroblasts (RASFs) were ob-
tained from RA patients undergoing arthroplasty who were diagnosed
based on criteria developed by the American College of Rheumatology
Diagnostic Subcommittee for Arthritis (33). Details of RASF isolation
and enrichment have been described previously (33) and were routinely
cultured in Dulbecco’s modified Eagle’s medium, 4.5 g/liter glucose,
L-glutamine, pyridoxine hydrochloride, 10% FCS, and antibiotics. NIH-
3T3 and HeLa cells (American Type Culture Collection) were cultured
as described above for RASFs.
Preparation of Cell Extracts and Western Blotting—Cellular proteins
(50–100 g) extracted in radioimmune precipitation assay buffer (50
mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1 mM phenylmeth-
ylsulfonyl fluoride, 10 g/ml aprotinin, g/ml leupeptin, g/ml pepsta-
tin, 1% Nonidet P-40, 1 mM sodium orthovanadate, and 1 mM NaF) or in
hot SDS-PAGE loading buffer from control and treated cells were sub-
jected to SDS-PAGE on 8–12% gels (16  20 cm, final concentration of
acrylamide) under reducing conditions and transferred onto nitrocellu-
lose membranes (Amersham Biosciences). Following blocking with 5%
BLOTTO for 2 h at room temperature and washing, the membranes
were incubated overnight at 4 °C with primary antibody in Tween/Tris-
buffered saline containing 0.25% BLOTTO. Horseradish peroxidase-
conjugated anti-rabbit secondary antibody (1:2000 dilution) was subse-
quently incubated with membranes for 1 h at room temperature and
washed extensively for 30–40 min with Tween/Tris-buffered saline,
followed by a final rinsing with Tris-buffered saline at room tempera-
ture. Following incubation with ECL chemiluminescence reagent (Am-
ersham Biosciences), membranes were prepared for autoradiography,
exposed to Kodak X-Omat film, and subjected to digital imaging system
(Alpha G-Imager 2000, Canberra Packard Canada, Mississauga, On-
tario, Canada) for semiquantitative measurements as described previ-
ously (33). Anti-Egr-1, anti-Sp-1, and anti-TNF- polyclonal antibodies
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Total (in-
dependent of phosphorylation state) and anti-phospho-Elk-1 (Ser383),
anti-phospho-ATF-2 (Thr69/71), anti-phospho-c-Jun (Ser63/73), and anti-
phospho-CREB-1 (Ser133) polyclonal antibodies were purchased from
Cell Signaling Technology (Waverly, MA).
Isolation of RNA and Northern Blotting—Total cellular RNA (1 106
cells  10–20 g of RNA) was isolated using TRIzol reagent as de-
scribed previously (33). Generally, 5–20 g of total RNA were resolved
on formaldehyde-containing 1.2% agarose gel and transferred electro-
phoretically (30 V overnight at 4 °C) to Hybond-NTM nylon membranes
(Amersham Biosciences) in 0.5 Tris acetate/EDTA (pH 7). After pre-
hybridization for 24 h, hybridizations were carried out at 50–55 °C for
24–36 h, followed by high stringency washing at 68 °C in 0.1 SSC and
0.1% SDS. The following probes, which were labeled with digoxigenin-
dUTP by random priming, were used for hybridization. Human TNF-
cDNA (1.3 kb), initially cloned into the HindIII and BamHI sites of
pFC54.t-1 (American Type Culture Collection), was released by diges-
tion. Human egr-1/krox-24 cDNA, initially cloned into the EcoRI sites of
Egr-1⁄Krox-24-mediated PGE2-dependent Suppression of TNF- 9537
 by guest on O
ctober 22, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the pMexNeoI vector (an Egr-1 expression vector; provided by Dr. D.
Skup, Department of Biochemistry, University of Montreal, Montreal,
Canada), contains 300 bp of 5-noncoding region and 580 bp of 3-
noncoding region of egr-1. Both the c-jun and junB probes were 2.6- and
1.9-kb cDNA fragments inserted into pGEM2 (American Type Culture
Collection). A 780-bp PstI/XbaI fragment from glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) cDNA (1.2 kb; American Type Culture
Collection) initially cloned into the PstI site of the pBR322 vector served
as a control for RNA loading, as GAPDH is constitutively expressed in
the cells used in these experiments. All blots were subjected to a digital
imaging system (Alpha G-Imager 2000) for semiquantitative measure-
ments, and changes in TNF- or egr-1 mRNA expression were always
considered as the ratio of GAPDH mRNA.
Extraction of Nuclear Proteins and Electrophoretic Mobility Shift
Assay (EMSA)—Confluent control and treated cells (3–5  106 cells/
well) in 4-well cluster plates were carefully scraped into 1.5 ml of
ice-cold phosphate-buffered saline and pelleted by brief centrifugation.
Nuclear extracts were prepared as described previously (33).
Double-stranded oligonucleotides containing wild-type (WT) and mu-
tant sequences were obtained from Invitrogen); annealed in 100 nM
Tris-HCl (pH 7.5), 1 M NaCl, and 10 mM EDTA at 65 °C for 10 min;
cooled for 1–2 h at room temperature; and finally end-labeled with
[-32P]ATP using T4 polynucleotide kinase (Promega, Madison, WI).
The sense sequences of the oligonucleotides tested were as follows:
consensus Egr-1/Krox-24, 5-GGA TCC AGC GGG GGC GAG CGG
GGG CGA-3; consensus mutant Egr-1/Krox-24, 5-GGA TCC AGC
GGG TAC GAG CGG GTA CGA-3; Egr-1/Krox-24 (TNF-), 5-GGA
TCG CCC CCC GCC CCC GCG CGA-3; mutant Egr-1/Krox-24 (TNF-
), 5-GGA TCG CCC TAC GCC CTA GCG CGA-3; ATF/CREB-like
(egr-1,131 bp), 5-GGG GGC TTC ACG TCA CTC CGG GT-3; mutant
ATF/CREB-like (egr-1), 5-GGG GGC TGA AGC TAG CTC CGG GT-3;
ATF-2/c-Jun-like (TNF-), 5-GAT TCA ATG AGC TCA CGG CTG
TG-3; and mutant ATF-2/c-Jun-like (TNF-), 5-GAT TCA AAG ACA
TCA CGG CTG TG-3. Binding buffer consisted of 10 mM Tris-HCl (pH
7.5), 50 mM NaCl, 0.5 mM dithiothreitol, 0.5 mM EDTA, 1 mM MgCl2, 4%
glycerol, and 2.5 g of poly(dI-dC). Binding reactions were conducted
with 15 g of nuclear extract and 100,000 cpm 32P-labeled oligonucleo-
tide probe at 22 °C for 20 min in a final volume of 10 l. For supershift
analysis, 2 g of affinity-purified anti-total/phospho-CREB-1 (1:1), anti-
total/phospho-ATF-2 (1:1), anti-total/phospho-c-Jun (1:1), anti-Egr-1, or
anti-Sp-1 polyclonal antiserum were incubated for 10 min with the
nuclear extracts prior to the addition of the radioactive probe. Binding
complexes were resolved by nondenaturing polyacrylamide gel electro-
phoresis on 6% gels in a Tris borate buffer system, after which the gels
were fixed, dried, and prepared for autoradiography.
Constructs, Transfections, and Reporter Assays—The PGK-puro vec-
tor, WT Egr-1/Krox-24, and dominant-negative mutants (WT minus the
zinc finger region and the zinc finger region only) were a kind gift from
Dr. D. Skup, and the construction of the plasmids has been described
previously (28). Briefly, human egr-1/krox-24 cDNA was removed from
the pMexNeoKrox-24 vector and inserted into the EcoRI site of the
PGK-puro vector (puromycin for selection), which utilizes the PGK
promoter to drive transcription, and thus generated the pPGK-Egr-1/
Krox-24 expression plasmid. The PGK-Egr-1/Krox-24 construct was
prepared by digesting pPGK-Egr-1/Krox-24 with XmnI and religating,
thus removing amino acids 271–364, corresponding to an essential part
of the zinc finger region. The PGK-zfEgr-1/Krox-24 construct was ob-
tained by preparing oligonucleotides corresponding to amino acids 210–
216 and 325–332 with the 5-nucleotide having the sequence 5-GGG
ATG-3 to provide a site for translational initiation, an EcoRI site, and
a BamHI site. The 3-oligonucleotide has an EcoRI and XbaI site. The
oligonucleotides were used to amplify the zinc finger region from pMex-
NeoKrox-24, and the resulting fragment was then cloned into BamHI/
XbaI-digested PGK vector. Sequencing confirmed that the insert was
correct and in-frame (28). Promoter constructs containing 1395 bp of the
egr-1/krox-24 promoter region along with925,636,459,252, and
77 deletion mutants were kindly provided by Dr. D. Skup, whereas
the pTNF615CAT construct was a gift from Dr. I. Kramer (Christian-
Albrechts Universitat, Kiel, Germany). Site-directed mutagenesis was
performed using the TransformerTM mutagenesis kit (Clontech) and
involved modifying the ATF/c-Jun site at bp 99 and 100 (CA3 TC)
and the Egr-1 site at bp 175 and 176 (CC 3 GG) of the
pTNF615CAT promoter fragment (615 to 34) and the ATF/CRE
site at bp 131 and 132 (CA 3 TC) of the egr-1 promoter (kindly
provided by Dr. D. Skup). cis-Reporter plasmids containing the lucifer-
ase reporter gene driven by a basic reporter element (TATA box) fused
to tandem AP-1-, ATF/CRE-, SRE-, and NF-AT-binding elements were
purchased from Stratagene. Constructs containing the transactivation
domains of transcription factors (e.g. ATF-2 and c-Jun) fused to the
Gal4 DNA-binding domain and driven by the cytomegalovirus promoter
(e.g. pFA-ATF-2) were used in decoy experiments as described previ-
ously (33). Finally, activated pMEK3 (MKK3/6) and pPKA-CAT expres-
sion plasmids (Stratagene, Upstate) were overexpressed to determine
the role in egr-1 promoter activity.
Transient transfection experiments were conducted in 4-, 6-, or 12-
well cluster plates as described previously (33) for adherent cell cul-
tures. Transfections were conducted using FuGENETM 6 (Roche Ap-
plied Science) or LipofectamineTM 2000 (Invitrogen) for 6 h according to
the manufacturers’ protocol with cells at 30–40% confluence. Cells
were re-exposed to culture medium and 1% FCS for 2 h prior to the
addition of the biological effectors. Transfection efficiencies were con-
trolled in all experiments by cotransfection with 0.5 g of pCMV--gal
(Stratagene), a -galactosidase reporter vector under the control of the
cytomegalovirus promoter. For stable transfections, selection was car-
ried out with 2 g/ml puromycin (PGK-puro vector), and experiments
were conducted in the presence of a maintenance level of 0.2 g/ml
puromycin.
THP-1 cells (10-g total plasmid concentration, 107 cells/0.5 ml in
RPMI 1640 medium, 10% FCS, and antibiotics) were transfected by
electroporation (Gene-Pulser II, Bio-Rad) using a 7-s pulse at 300 V and
960 microfarads. Where appropriate, transfectants were selected with
puromycin as described previously (23, 28). The TNF- and egr-1 pro-
moter activities were assessed by measuring CAT protein using
enzyme-linked immunosorbent assay (Roche Applied Science) or by
measuring CAT activity using [14C]chloramphenicol and thin-layer
chromatography, followed by enhanced autoradiography (Amersham
Biosciences), according to the manufacturers’ instructions. Luciferase
values, expressed as enhanced relative light units, were measured in a
Lumat LB 9507 luminometer (EG&G, Stuttgart, Germany) and nor-
malized to the level of -galactosidase activity (absorbance at 420 nm
after a 24-h incubation with o-nitrophenyl -D-galactopyranoside and
conversion to o-nitrophenol) and cellular protein (bicinchoninic acid
procedure, Pierce).
Statistical Analysis—All results are expressed as the mean S.D. or
the mean and coefficient of variation of three to five separate experi-
ments as indicated. Transfection experiments were performed in trip-
licate. Statistical treatment of the data was performed by parametric
(Student’s t test) or non-parametric (Mann-Whitney) analysis if gauss-
ian distribution of the data could not be confirmed. Significance was
acknowledged when the probability was 	5%.
RESULTS
PGE2 Induces egr-1 mRNA Expression and Synthesis: Time
and Dose Dependence—Before examining the role of Egr-1 in
PGE2-dependent suppression of TNF- expression, we first
characterized the kinetics (and mechanism) of PGE2 induction
of the egr-1 gene in clinically significant cell phenotypes. We
performed both dose-response and time course studies using
primary cell culture models consisting of human peripheral
monocytes/macrophages and RASFs. As shown in Fig. 1A,
PGE2 induction of the egr-1 gene was dose-dependent, and the
EC50 for PGE2-dependent egr-1 mRNA expression in either
monocyte/macrophage or RASF cultures was 46  12 nmol/
liter (mean S.D., n 6). For all subsequent experimentation,
2  EC50 (90% response saturation) was chosen unless
otherwise indicated. The PGE2-dependent induction of Egr-1
protein followed a dose-response profile similar to that of
egr-1 mRNA expression as judged by Western blot analysis,
whereas Sp-1, a GC box-binding transcription factor, was
unaffected (Fig. 1B). Time course studies revealed rapid rises
(5 min) in egr-1 mRNA (3.8 kb) expression following PGE2
treatment, which increased to 
10-fold over control levels
after 15 min and attained steady state after 30 min, followed
by a precipitous and rapid decay to near control levels.
Modest levels of egr-1 mRNA were also observed after 4 h of
PGE2 stimulation (Fig. 1C). Specific binding to a consensus
Egr-1 enhancer 32P-labeled oligonucleotide was detected by
30 min and persisted up to 8 h as judged by EMSA (Fig. 1D,
upper and lower left panels). EMSA supershift analysis con-
firmed the identity of the binding species as Sp-1 and Egr-1
(Fig. 1D, lower right panel). No Sp-1 oligonucleotide binding
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changes were observed with increased Egr-1 binding (i.e. no
displacement) following PGE2 treatment.
PGE2 Induces egr-1 mRNA Expression through Activation of
the MKK3/SAPK2/p38 MAPK Pathway and Transactivation of
5-Flanking Promoter Sequences—To examine for elements
of transcriptional control of PGE2-stimulated egr-1 expression,
we conducted transient transfection analyses in THP-1 cells
using a series of deletion mutants of the egr-1 promoter. As
shown in Fig. 2A, the egr-1 promoter harbors a number of
enhancer sites, including nested SRE, AP-1, AP-2, ATF-2/CRE,
Egr-1, and other GC-rich sequences. Upon stimulation with
PGE2, elevated induction of CAT protein was observed with the
pCAT252 (SmaI) fragment (3.21  0.63-fold; mean  S.D. for
three experiments in duplicate) and the925 mutant fragment
(3.85  0.78-fold). For comparison purposes, we repeated the
experiments with 100 nmol/liter PMA, a well known stimulator
of Egr-1 (25, 26), and found maximal induction with the
pCAT459 construct (1.99 0.14-fold). As shown diagrammat-
ically in Fig. 2A, the pCAT252 (SmaI) fragment has an ATF-
2/CRE site at bp 138 to 131 in addition to at least one SRE
site and a proximal GC box (bp 64 to 46). Because the data
from Fig. 2A (see pCAT77) suggest that the Sp-1 site was not
responsive to PGE2 (see also Fig. 1, B and D), we investigated
whether ATF-2/CRE and/or SRE sites are crucial for promoter
activation. As shown in Fig. 2B, promoter activation by PGE2
was substantially decreased (
85%) when the ATF-2/CRE site
was mutated. Overexpression of pMEK3 (MKK3) and, to a
lesser extent, pPKA-CAT increased WT egr-1 promoter activity
(pCAT252), whereas, as in the case with PGE2, mutating the
ATF-2/CRE site abrogated the inductive response (Fig. 2B).
The addition of SB 202190 (100 nmol/liter) reversed the induc-
tive effects of PGE2 (332  51 (PGE2) versus 65  27 (SB
202190) pg of CAT protein).
In view of the presence of the SRE sites in the pCAT252
constructs and the possibility that the serum response factor
may contribute in some way to PGE2-dependent promoter in-
duction, we conducted further studies with transfected reporter
plasmids harboring five tandem SREs. This approach gives a
very sensitive measure of cell signaling and transactivation by
specific transcription factors. As shown in Fig. 2C, PGE2 did
not transactivate the SRE reporter as judged by measuring
luciferase activity, nor did it modify serum-induced phospho-
rylation of Elk-1 (Fig. 2D), a potent SRE-binding factor and
transactivator in RASFs.
We next investigated whether PGE2 can up-regulate and
phosphorylate nuclear binding proteins that bind specifically to
the ATF-2/CRE site (bp 138 to 131) using Western and
EMSA analyses. Previous work from our laboratory has shown
that PGE2 rapidly activates the SB 202190-sensitive SAPK2/
p38 MAPK cascade through EP4 receptor cell-surface binding
in inflammatory cell phenotypes (21). As shown in Fig. 3A,
PGE2 induced a very rapid phosphorylation of ATF-2 at
Thr69/71 and a slightly more delayed phosphorylation of ATF-
1/CREB-1 at Ser133 (5 min). Furthermore, PGE2 increased
nuclear protein binding to the ATF-2/CRE-like oligonucleotide,
and supershift analysis revealed that the principal binding
species appeared to be ATF-2, with an apparently lesser
FIG. 1. Dose response (A and B) and time course (C and D) of
PGE2 stimulation of egr-1/krox-24 mRNA and protein. Cultured
confluent second passage human RASFs (1.2  106 cells in 6-well
cluster plates) were preincubated for 4 h in Dulbecco’s modified Eagle’s
medium supplemented with 1% FCS plus antibiotics at 37 °C to ensure
synchrony and quiescence. Cells were then treated with increasing
concentrations of PGE2 (0–20 mol/liter) for 30 min, and monolayers
were extracted for RNA (A) or protein (B). In C and D, cells were
incubated with PGE2 for varying time periods (0–16 h). Total RNA (5
g) was analyzed for egr-1/krox-24 mRNA by Northern hybridization
using a specific digoxigenin-labeled cDNA probe as described under
“Materials and Methods” (A and C), and 50 g of protein were analyzed
for Egr-1/Krox-24 protein by Western blotting using specific polyclonal
antisera for Egr-1 and Sp-1 (B). In D, 15 g of nuclear protein were
subjected to EMSA using consensus and mutant (mut) 32P-labeled Egr-
1/Krox-24 oligonucleotides, and gel supershift assays were performed
with specific anti-Egr-1 and anti-Sp-1 antisera as described under “Ma-
terials and Methods.” Con, control.
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amount of CREB-1 (Fig. 3B). In support of this, PGE2 induction
of egr-1 mRNA was markedly reduced to control levels by
co-incubations with SB 202190 (Fig. 3C) (see Ref. 33). The
preferential protein kinase A inhibitor KT5720 had a more
modest inhibitory effect in this regard. Phorbol ester (PMA)
stimulation of egr-1 expression was abrogated by co-incuba-
tions with calphostin C, a preferential inhibitor of the most
prevalent isoforms of protein kinase C (34), but not by protein
kinase A and p38 MAPK inhibitors (Fig. 3C).
PGE2 Transcriptionally Suppresses rhIL-17-induced TNF-
mRNA Expression: Role of Egr-1 and AP-1 Family Members—
Supported by the strong data on the mechanism of PGE2 con-
trol of Egr-1 expression, we turned our attention to the putative
role of Egr-1 in PGE2-dependent suppression of cytokine-in-
duced TNF- expression and release. In this regard, a number
of studies have shown that cAMP-elevating agents inhibit in-
duced TNF- expression, although the precise mechanism is
complex and largely ill defined (reviewed in Ref. 35). Although
PGE2 can indeed elevate cAMP levels in a number of cell
phenotypes, it also activates the p38 MAPK cascade and in-
duces signaling cross-talk within the MAPK cascades (this
work and Ref. 21). Recent results from our laboratory have
provided physiological relevance to the latter reports to the
extent that when freshly explanted osteoarthritis- or RA-af-
fected synovial membranes were treated with preferential
COX-2 inhibitors, a marked induction of TNF- and interleu-
kin (IL)-1 release was observed (36). Furthermore, lipo-
polysaccharide (LPS)-induced release of TNF- and IL-1 was
augmented 
4-fold in the presence of the COX-2 inhibitor. The
addition of PGE2 returned levels to the base line, and thus,
strong evidence was provided that TNF- is an eicosanoid-
dependent gene.
In this series of experiments, we used our previously de-
scribed paradigm in which the CD45 T memory cell-derived
pro-inflammatory cytokine IL-17 was used to stimulate TNF-
expression, synthesis, and release by human monocytes/macro-
phages (32). As shown in Fig. 4A, increased TNF- transcripts
FIG. 2. PGE2 induction of the egr-1 promoter: role of ATF-2/
CRE and SRE. THP-1 cells (107 cells/0.5 ml), cultured in RPMI 1640
medium, 10% FCS, and antibiotics, were transfected with various de-
letion mutants of the egr-1 promoter by electroporation using 10 g of
total plasmid and a 7-s pulse at 300 V and 960 microfarads. Transfec-
tion efficiencies were controlled in all experiments by cotransfection
with 0.5 g of pCMV--gal. Cells were allowed to recover for 24 h in
complete medium, after which the cells were maintained under low
serum conditions (1% for 3 h) and then treated with PGE2 or PMA (100
nmol/liter) for 6–8 h. In A, cells were washed and lysed, and egr-1
promoter activity was assessed by measuring CAT protein using a
specific and sensitive enzyme-linked immunosorbent assay. In B, cells
were cotransfected with 10 g of egr-1 promoter construct pCAT252 or
mutant (mut) CRE (131) pCAT252 plasmid; 2 g of pCMV, pMEK3,
or pPKA-CAT; and 0.5 g of pCMV--gal as described above. After 24 h,
cells were maintained under low serum conditions (1% for 3 h) and then
assayed for CAT protein. Cells were also treated with 100 nmol/liter
PGE2 alone or with 100 nmol/liter SB 202190 for 6 h as indicated. In C,
cells were transfected with 10 g of ptkSRE(5X)-LUC reporter and 0.5
g of pCMV--gal as described above. Following recovery and mainte-
nance under low serum conditions, cells were treated with vehicle, 100
nmol/liter PGE2, or 10% serum for 6 h, and luciferase (LUC) values
(expressed as enhanced relative light units (RLU)) were measured in a
Lumat LB 9507 luminometer and normalized to the level of -galacto-
sidase (-gal) activity (absorbance at 420 nm after 24 h) and cellular
protein (bicinchoninic acid procedure). In D, cells were stimulated with
vehicle (control), 10% serum, 10% serum  PGE2 (100 nmol/liter), or
PGE2 (100 nmol/liter) for 1 h, after which whole cell lysates were
subjected to Western analysis using specific antibodies to phospho-
Elk-1 (Ser383) and Elk-1 as described under “Materials and Methods.”
Probabilities were calculated by Student’s t test and represent trans-
fectants with the indicated promoter construct that were treated versus
untreated (i.e. -fold induction). A: *, p 	 0.02; **, p 	 0.05. B: *, p 	
0.034; **, p 	 0.05; #, p 	 0.001 versus pCMV; , p 	 0.002 versus
pMEK3 WT egr-1 promoter; , p 	 0.02 versus pPKA-CAT and PGE2
WT egr-1 promoter; ##, p 	 0.01 versus PGE2 WT egr-1 promoter. C: #,
p 	 0.001 versus ptkSRE(5X)-LUC.
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were observed after 15–30 min, reaching steady state at 2–4
h, followed by rapid decay. Immunoreactive TNF- protein
could be detected after 30 min, with levels being apparently
constant after 4–8 as judged by Western analysis of condi-
tioned medium (Fig. 4A). Co-incubations of rhIL-17-treated
human monocytes/macrophages with increasing concentra-
tions of PGE2 led to dose-dependent suppression of induced
TNF- mRNA levels. In both human macrophages and RA-
affected synoviocytes, the IC50 for TNF- suppression was
45  12 nmol/liter (mean  S.D., n  4) (Fig. 4, B and C).
Recent work from our laboratory has confirmed that PGE2
controls gene expression at transcriptional and post-transcrip-
tional levels (message stability) (21). As a first approach to
verify whether transcriptional mechanisms are involved in the
potent PGE2-dependent inhibition of rhIL-17-induced TNF-
expression, studies were conducted with the TNF- promoter
pTNF615SVOCAT in transiently transfected THP-1 cells
treated with rhIL-17 with or without increasing concentrations
of PGE2. Using the intact promoter, rhIL-17 induced a 
5-fold
increase in CAT (protein) reporter synthesis, an effect abro-
gated by mutation of the ATF-2/c-Jun-like enhancer site (Fig.
5A). The addition of PGE2 decreased rhIL-17-stimulated CAT
protein synthesis (WT construct) in a dose-dependent fashion,
with 
95% inhibition at 100–1000 nmol/liter (Fig. 5A). Inter-
estingly, mutating the Egr-1 site in the promoter did not com-
FIG. 3. PGE2 stimulates increased phosphorylation of ATF-2/
CREB and increased binding to an egr-1 promoter-specific ATF-
2/CRE 32P-labeled oligonucleotide. In A, quiescent RASFs were
treated with or without PGE2 (100 nmol/liter) for varying time periods
up to 60 min, after which cells were lysed, and 50 g of protein were
analyzed by Western analysis using specific antiserum to phospho-
ATF-2 (Thr69/71), phospho-ATF-1 (Ser133)/CREB-1, and CREB-1. In B,
cells were stimulated with PGE2 (100 nmol/liter) for 0–40 min, after
which nuclear proteins were extracted, and EMSA and supershift anal-
yses were performed as described under “Materials and Methods.” mut,
mutant. In C, cells were treated for 30 min with vehicle (left lane); 100
nmol/liter PMA; 100 nmol/liter PGE2; PMA  PGE2; PMA in the pres-
ence of 100 nmol/liter calphostin C (Cal C), 100 nmol/liter SB 202190, or
2 mol/liter KT5720; or PGE2 in the presence of calphostin C, SB
202190, or KT5720. Monolayers were extracted for RNA, and 5 g of
total RNA were analyzed for egr-1 and GAPDH mRNAs by Northern
hybridization using specific digoxigenin-labeled cDNA probes as de-
scribed under “Materials and Methods.”
FIG. 4. PGE2 inhibits rhIL-17-stimulated TNF- expression in
humanmonocytes/macrophagesandRASFs inapotentanddose-
dependent fashion. In A, human monocytes/macrophages (1.2  106
cells/well) in monolayer cultures were treated with rhIL-17 (50 ng/ml)
for varying time periods (0–24 h). Cells were extracted for total RNA,
and 2 g were analyzed for TNF- and GAPDH mRNAs by Northern
hybridization using specific digoxigenin-labeled cDNA probes as de-
scribed under “Materials and Methods.” Spent culture medium was
collected and analyzed by Western blotting for TNF- using a specific
antiserum. In B and C, human monocytes/macrophages and RASFs,
respectively, were treated for 4 h with or without 50 ng/ml rhIL-17 in
the absence or presence of increasing concentrations of PGE2. Total
RNAs at 2 (B) and 20 (C) g were analyzed for TNF- and GAPDH
mRNAs by Northern hybridization.
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FIG. 5. Transcriptional repression of rhIL-17-induced TNF- gene expression by PGE2: role of Egr-1. In A, THP-1 cells (5  10
7
cells/0.5 ml), cultured in RPMI 1640 medium, 10% FCS, and antibiotics, were transfected by electroporation with 10 g of total WT, mutant (mut)
Egr-1, and mutant ATF-2/c-Jun pTNF615SVOCAT plasmids using a 7-s pulse at 300 V and 960 microfarads. Transfection efficiencies were
controlled in all experiments by cotransfection with 0.5 g of pCMV--gal construct. Cells were allowed to recover for 24 h in complete medium,
after which they were maintained under low serum conditions (1% for 3 h) and then treated with or without rhIL-17 (50 ng/ml) in the absence or
presence of increasing concentrations of PGE2 for 6 h. Cells were washed and lysed, and promoter activities were assessed by measuring CAT
protein using a specific and sensitive enzyme-linked immunosorbent assay. -Galactosidase (-gal) activity was measured as described under
“Materials and Methods.” Con, control. In B, THP-1 cells (107 cells/0.5 ml) or THP-1 cells stably transfected with a eukaryotic expression vector
(PGK vector, PGK-Egr-1, PGK-zfEgr-1, or PGK-Egr-1) were incubated with or without rhIL-17 (50 ng/ml) in the presence or absence of PGE2 (100
nmol/liter) for 4 h, after which the cells were extracted for total RNA, and 5 g were analyzed for TNF- and egr-1 mRNAs by Northern
hybridization using specific digoxigenin-labeled cDNA probes as described under “Materials and Methods.” In C, NIH-3T3 cells (106 cells/well)
stably transfected with a eukaryotic expression vector (PGK vector, PGK-Egr-1, PGK-zfEgr-1, or PGK-Egr-1) were transiently cotransfected with
10 g of WT or mutant Egr-1 site pTNF615SVOCAT plasmid using LipofectamineTM 2000 for 6 h according to the manufacturer’s protocol with
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pletely abrogate PGE2-dependent inhibition of induced pro-
moter activity (Fig. 5A).
To better characterize the putative role of Egr-1 in mediating
direct PGE2 inhibition of TNF- expression, we chose to use
THP-1 cells stably transfected with eukaryotic expression con-
structs of WT Egr-1 and dominant-negative mutants (see “Ma-
terials and Methods”). As shown in Fig. 5B, the suppressive
effects of PGE2 on TNF- mRNA expression were reversed
significantly by the dominant-negative mutants PGK-Egr-1
and PGK-zfEgr-1, and the blockade was essentially complete
when both were transfected in tandem. Moreover, high level
expression of WT PGK-Egr-1 in THP-1 cells inhibited rhIL-17-
induced TNF- mRNA expression as efficiently as did PGE2
(Fig. 5B).
Because the latter experiments did not rule out the possibil-
ity that overexpressed Egr-1 constructs affect TNF- mRNA
stability (as distinct from the transcriptional control), we chose
to repeat these experiments with stable NIH-3T3 trans-
formants expressing Egr-1 (PGK-Egr-1) and the dominant-
negative mutants PGK-Egr-1 and/or PGK-zfEgr-1, in which,
however, the TNF- promoter construct was transfected tran-
siently. Our aim was to use a cell culture model that does not
express TNF- mRNA normally (eliminating low signal-to-
noise ratios) and in which substantial transient transfection
efficacy can be attained. PGK-Egr-1 reduced rhIL-17-stimu-
lated WT pTNF-SVOCAT activity to near vehicle levels,
mimicking to a large degree the effects of PGE2 in this regard
(Fig. 5C). The dominant-negative mutants PGK-Egr-1 and
PGK-zfEgr-1, alone or in combination, substantially reversed
the inhibitory effects of exogenously added PGE2. Both CAT
protein and CAT activity measurements gave very similar re-
sults. However, as in the data shown in Fig. 5A, mutating the
Egr-1 site did not completely reverse PGE2/Egr-1-dependent
inhibition of rhIL-17-induced promoter activity. As shown in
Fig. 5D, the level of expression of all the Egr-1 and mutant
constructs was quite substantial (and adequate) compared with
endogenous expression of Egr-1 in untreated cells and was
represented essentially stoichiometrically in cells treated
with PGE2.
Thus, the previous results presented us with a conundrum:
on the one hand, the data provided strong evidence that Egr-1
mediated the inhibitory effects of PGE2 on induced TNF-
mRNA expression, whereas on the other, PGE2-stimulated
Egr-1 binding to its cognate site in the TNF- promoter was not
wholly adequate for complete (induced) promoter suppression.
We thus explored the possibility that PGE2/Egr-1 may disrupt
the rhIL-17-stimulated TNF- transcriptional enhancer com-
plex. In preliminary experiments using NIH-3T3 cells overex-
pressing “decoy” constructs (see Ref. 33 using a human synovial
fibroblast cell strain) that harbor the transactivation domains
of ATF-2, c-Jun, CREB-1, Elk-1, and c-Fos fused to the Gal4
DNA-binding domain, we observed that rhIL-17 induction of
the TNF- promoter CAT activity was blocked by pSV40-Gal4-
ATF-2-(1–96) and pSV40-Gal4-c-Jun-(1–223) (compare 0.71 
0.22 (control) and 6.3  0.79 (rhIL-17) normalized CAT protein
at ng/g of cellular protein versus 0.65  0.19 (ATF-2; p 	
0.0002); 3.1  0.75 (c-Jun; p 	 0.043), 5.4  1.09 (CREB-1),
6.6  1.2 (c-Fos), and 6.1  2.1 (Elk-1)). Gel shift experiments
were undertaken to substantiate the latter findings; and as
shown in Fig. 6A, rhIL-17 increased the binding to an ATF-2/
c-Jun-like 32P-labeled oligonucleotide of the human TNF- pro-
moter. Substantial supershifted low mobility banding was ob-
served with anti-phospho-ATF-2 (Thr69/71) and anti-phospho-c-
Jun (Ser63/73) antibodies, but not with anti-phospho-CREB-1
(Ser133) antibody (Fig. 6A, upper panel). The addition of PGE2
and overexpression of PGK-Egr-1 blocked rhIL-17-stimulated
binding to the ATF-2/c-Jun-like 32P-labeled oligonucleotide to a
substantial degree (Fig. 6A, lower left panel). The inhibitory
effect of PGE2 was markedly abrogated in cells stably trans-
fected with the dominant-negative mutants PGK-Egr-1 and
PGK-zfEgr-1, alone or in combination (Fig. 6A, lower right
panel).
We next examined the possible role of Egr-1 in the mediation
of PGE2 effects on c-Jun (AP-1) using NIH-3T3 transformants
expressing Egr-1 (PGK-Egr-1) and the dominant-negative mu-
tants PGK-Egr-1 and PGK-zfEgr-1, alone or in combination.
As shown in Fig. 6B, rhIL-17-induced c-jun mRNA expression
was suppressed by PGE2, an effect mimicked by Egr-1, but
compromised by the Egr-1 dominant-negative mutants. In tan-
dem comparative studies, junB, a wholly inducible gene and
potent transcriptional repressor of c-Jun transactivation activ-
ity (37), was not responsive to rhIL-17 treatments, but was
up-regulated by Egr-1 overexpression. Furthermore, PGE2
markedly up-regulated the steady-state expression of junB
mRNA, and the effect was reversed by the Egr-1 dominant-
negative mutants. JunB was not detectable in gel shift exper-
iments (data not shown).
DISCUSSION
There is now wide agreement that TNF- is a key cytokine
mediator in the immune and inflammatory responses, initiating
a cascade of processes that ultimately serve to eliminate the
invading pathogen and to re-establish a state of homeostasis in
the organism (4, 5). However, in chronic and systemic inflamma-
tory states, such as those seen in RA, excess TNF- production is
believed to be associated with disease pathogenesis, and reme-
dial results have been reported with disease-modifying anti-
TNF- therapies (38). Somewhat paradoxically, we recently re-
ported that TNF- production by synovial membrane/pannus
explants from osteoarthritis/RA patients was very modest, but
could be increased markedly by treating the explants with pref-
erential COX-2 inhibitors, a process reversed by exogenously
added PGE2 (36). Furthermore, LPS-stimulated release of TNF-
was increased 4–5-fold in the presence of the COX-2 inhibitors, a
response strongly reversed by exogenous PGE2. Given the clini-
cally relevant nature of the studies, we concluded that TNF-
expression is largely eicosanoid-dependent. Thus, the present
work is a logical extension of our previous studies (16, 23, 36) and
delves into the complex and novel mechanistic details of PGE2
regulation of TNF- synthesis.
The production of TNF- is controlled transcriptionally, post-
transcriptionally (mRNA stability), and translationally and by
post-translational processing (TNF--converting enzyme), al-
though the precise mechanisms involved remain a challenge for
cells at 30–40% confluence. Cells were then re-exposed to culture medium and 1% FCS for 2 h to ensure quiescence and synchrony prior to the
addition of rhIL-17 (50 ng/ml) with or without PGE2 (100 nmol/liter) as indicated, and cells were extracted after 16 h for analysis of CAT protein
and activity as described under “Materials and Methods.” In D, NIH-3T3 cells stably transfected with the PGK vector, PGK-Egr-1, PGK-zfEgr-1,
or PGK-Egr-1 were extracted for total RNA; 5 g were analyzed for egr-1/krox-24 mRNA by Northern hybridization using a specific digoxigenin-
labeled cDNA probe as described under “Materials and Methods,” and 50 g of protein were analyzed for Egr-1/Krox-24 protein by Western blotting
using a specific polyclonal antiserum to Egr-1 (purified Egr-1 protein; first and last lanes). Probabilities were calculated by Student’s t test. B: ¶,
p	 0.0001 versus control WT construct; #, p	 0.04 versus rhIL-17WT construct; &, p	 0.001 versus rhIL-17WT construct. C: **, p	 0.0027 versus
vehicle; , p 	 0.005 versus rhIL-17; ¶, p 	 0.043 versus rhIL-17 with mutant Egr-1; , p 	 0.01 versus rhIL-17 with PGE2; %, p 	 0.027 versus
rhIL-17 with PGE2; $, p 	 0.0025 versus rhIL-17 with PGE2.
Egr-1⁄Krox-24-mediated PGE2-dependent Suppression of TNF- 9543
 by guest on O
ctober 22, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
future research. Here, we have reported that the T-cell-derived
pro-inflammatory cytokine IL-17 up-regulated TNF- expres-
sion and synthesis in human macrophages and RASFs largely
through ATF-2/c-Jun-dependent transactivation at a 5-
TGAGCTCA-3 palindrome of the TNF- promoter. In previous
reports, IL-17 stimulated ATF-2/CREB-1-dependent transacti-
vation of the COX-2 promoter at a 5-TTTCGTCA-3 site, and
the cytokine cell signaling profile was also restricted to the p38
MAPK cascade in a number of different fibroblast and mesen-
chymal phenotypes (33). As an example of the complexity and
subtlety of cell signaling, the PGE2-targeted site of the egr-1
promoter (5-TCACGTCA-3) binds preferentially, although not
exclusively, ATF-2 dimers, the latter phosphorylated by p38
MAPK, arguing that signaling intermediates may be “selected”
at the level of the promoter sequence.
Several studies suggest that IL-17 signals through NF-B,
and this may be of some significance because the TNF- pro-
moter has three putative NF-B-like binding sites (39, 40).
However, in all cell types we are concerned with, IL-17 activa-
tion of NF-B is modest, delayed, or inhibited, whereas others
have shown that these putative enhancer sites do not mediate
the induction of the human TNF- promoter by substances
known to activate NF-B (i.e. LPS) (see Refs. 32, 40, and 41). In
support of this, it was recently shown that CREB-binding pro-
tein/p300 mediates LPS induction of TNF- through assembly
of an enhancer complex that includes Ets-1/Elk-1 binding to an
NF-AT site, ATF-2/c-Jun dimer binding to the ATF-2/CRE site,
and GC box-binding transcription factors in murine monocytic
J774/P338D cells (41). It would be of interest, however, to
determine whether the latter response is species-specific, as
LPS signals through Toll-like receptor-4 in human macro-
phages and activates the NF-B cascade (42). Interestingly,
TNF- controls it own synthesis (autoregulation), and a puta-
tive palindrome that resembles an ATF/CRE site (bp 125 to
82) apparently mediates TNF--dependent promoter induc-
tion (43); the transactivation factors were identified as exclu-
sively c-Jun-related proteins. The observed discrepancies may
be the result of cell context, and it seems likely that a gene can
respond to multiple signaling cascades through the recruit-
ment of different proteins to similar enhancer elements. It
should also be mentioned that there are data demonstrating
ATF-2/c-Jun transactivation at AP-1 sites of certain promoters
as well (44).
As a transcription factor, Egr-1 induces the promoter activity
of prostaglandin E synthase directly by binding to tandem GC
boxes in the proximal promoter (10), but can act in combinato-
rial fashion with other transcription factors, as in the case of its
own expression in granulosa cells subsequent to follicle-stimu-
lating hormone and luteinizing hormone stimulation (46). In
the latter system, Egr-1 associates with Sp-1 to bind a proximal
GC box and together with an enhancer complex involving
CREB and serum response factor to drive egr-1 mRNA expres-
sion. This paradigm is not well suited to our results, as PGE2
stimulation of Egr-1 protein was delayed by 30 min, whereas
PGE2-dependent transcriptional induction of egr-1 mRNA was
rapid. Our data favor the rapidly induced p38 MAPK pathway
with ATF-2/CREB transactivation of the egr-1 promoter at
cognate sites, although the increase in egr-1 mRNA seen at 4 h
may be Egr-1-driven. In stromal cells, up-regulated macro-
phage colony-stimulating factor gene expression by TNF- or
IL-1 involves Sp-1-dependent promoter transactivation, and
this occurs subsequent to Egr-1 phosphorylation and dissocia-
tion from Sp-1, resulting in higher levels of free, transcription-
ally active Sp-1 (47). In contrast, Sp-1 and Egr-1 have opposing
effects on the regulation of the multidrug resistance gene
MDR1, where the latter transcription factor suppresses MDR1
promoter activity, and the former activates it (48). Sp-1 expres-
sion in our cell culture models is constitutive, and its binding to
GC-rich sequences (Egr-1 or TNF- promoters presumably)
appears to be unchanged under the treatments we used. We
can not rule out the possibility, however, that Sp-1 transacti-
vation activity may be modified by phosphorylation/glycosyla-
FIG. 6. Disruption of rhIL-17-induced binding to a TNF- pro-
moter-specific ATF-2/c-Jun 32P-labeled oligonucleotide by
PGE2: role of Egr-1-mediated suppression of c-jun mRNA ex-
pression. In A, quiescent RASFs were treated with rhIL-17 or vehicle
(control (C)) for 60 min, after which nuclear proteins were extracted,
and EMSA and supershift analyses (using an ATF-2/c-Jun sequence
oligonucleotide probe and the indicated antibodies) were performed as
described under “Materials and Methods” (upper panel). Quiescent
NIH-3T3 cells (106 cells/well) or cells stably transfected with a eukary-
otic expression vector (PGK-Egr-1, PGK-zfEgr-1, or PGK-Egr-1) were
treated with vehicle with or without rhIL-17 (50 ng/ml) in the presence
or absence of PGE2 (100 nmol/liter) for 60 min as indicated (lower
panels). Nuclear extracts were prepared, and EMSA was performed.
mut, mutant. In B, quiescent NIH-3T3 cells (106 cells/well) or cells
stably transfected with a eukaryotic expression vector (PGK vector,
PGK-Egr-1, PGK-zfEgr-1, or PGK-Egr-1) were treated with vehicle or
with rhIL-17 in the presence or absence of PGE2 for 30 min as indicated.
Cells were extracted for total RNA, and 5 g were analyzed for c-jun,
junB, and GAPDH mRNAs by Northern hybridization using specific
digoxigenin-labeled cDNA probes as described under “Materials and
Methods.”
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tion subsequent to PGE2 stimulation (or Egr-1 overexpression).
A previous study reported that transient Egr-1/Krox-24 over-
expression in Jurkat T-cells could increase TNF- promoter
activity, although deletion mutants failed to ascribe the induc-
tive effect to the Egr-1 site in the promoter (29). Given the
problems inherent in transient overexpression with cotrans-
fected promoter constructs (e.g. low efficiency), we chose the
more laborious route of stable transfectants with the goal of
obtaining consistent results. Well tested procedures (28, 49)
were used to ensure amplification of those clones in which egr-1
mRNA expression was substantial and Egr-1 protein was ob-
tained while at the same time not inducing background expres-
sion as a result of transfection. The PGK-Egr-1/Krox-24 mu-
tant has been shown to interact with endogenous Egr-1 and to
reduce its transactivation capacity in reporter studies, whereas
the PGK-zfEgr-1/Krox-24 mutant probably saturates cognate
enhancer-binding sites (28, 49). The culture system afforded us
strong evidence that PGE2 suppression of induced TNF-
mRNA expression occurs through a transcriptional mechanism
involving the Egr-1-mediated inhibition of c-Jun expression
and disruption of the IL-17-activated transactivation complex
(Fig. 7). The concomitant induction of JunB, a transcriptional
repressor (50), became evident on a tandem mRNA screen and
is likely mediated by an Egr-1 site in the proximal promoter
region (51). Whether JunB, which binds DNA very weakly (50),
competes with c-Jun for ATF-2 dimerization and thus causes
DNA binding displacement is under further study.
Recent studies suggest that PGE2, via the EP4 receptor,
induces egr-1 expression via activation of phosphatidylinositol
3-kinase, ERK1/2, and glycogen synthase kinase-3 (24). Down-
stream targets of this activation include cyclin D and T-cell
factor (52). Considering the data presented here and our pre-
vious reports (16, 21), PGE2 seems to induce Egr-1 synthesis by
rapid activation of the MLK3/MKK3/SAPK2/p38 MAPK/
MSK1 cascade with strong ATF-2/ATF-2:ATF-2/CREB-1 trans-
activation of the target promoter. However, PGE2 also stimu-
lates MEK1/2 and ERK1/2 phosphorylation, but is delayed by
1 h in our cell culture models (16), and preliminary results
suggest that the eicosanoid drives ERK1/2 ubiquitination and
proteasomal processing, as if to terminate an extraneous sig-
nal. We propose that PGE2, acting via feedback or feed-forward
mechanisms, interdicts the pro-inflammatory response of cyto-
kines by shutting down cytokine-activated cascades, i.e. p38
MAPK via MKK3 inhibits JNK1 phosphorylation and AP-1
activity and turns off c-Jun-targeted genes. The latter scenario
may represent one of many cellular pathways ensuring home-
ostasis: differentiation and developmental signals counterbal-
ancing transformational/oncogenic cues.
Whether Egr-1 has a role to play in the acute or chronic
inflammatory response remains a subject for further research;
however, a number of observations may be informative. The
RA-affected synovial membrane/pannus expresses markedly
elevated levels of egr-1 mRNA (53),2 whereas other oncogenes
such as c-jun and c-fos, for example, are not detectable. COX-2
protein and ambient PGE2 levels are extremely high, whereas
pro-inflammatory cytokine production is very low until, as
mentioned above, preferential COX-2 inhibitors suppress PGE2
production (36). Egr-1-null mice have compromised pituitary-
adrenal axis function (45), presumably leading to a suboptimal
2 J. A. Di Battista, unpublished data.
FIG. 7. Proposed mechanism of PGE2-dependent suppression of IL-17-induced TNF- synthesis in human macrophages. In human
RA-affected synovial membranes, CD45 T-lymphocyte-derived IL-17 activates a resident macrophage/synovial cell to produce TNF- through
strong ATF-2/c-Jun-dependent promoter transactivation (rapid response). In tandem, the cytosolic phospholipase A2 (cPLA2)/COX-2/prostaglandin
E synthase (PGES) cascade is stimulated, with the resultant production of PGE2 (delayed). Through an EP4 receptor-mediated negative feedback
loop, PGE2 activates the MLK3/MKK3/p38 MAPK and protein kinase A signaling pathways. This results, more or less simultaneously, in the
possible inhibition of c-Jun phosphorylation (1), stimulation of Egr-1 synthesis through ATF-2/ATF-2:ATF-2/CREB-dependent promoter transac-
tivation (2), and Egr-1 inhibition of c-jun mRNA expression (3) likely through promoter suppression and disruption of the IL-17-induced
ATF-2c-Jun enhancer complex (4). The mechanism of Egr-1 binding and partial TNF- promoter suppression remains to be determined (5). Thick
arrows indicate strong experimental support, whereas broken lines/thin arrows indicate putative mechanisms. The proposed mechanism is
consistent with our previous observations (36) regarding the autocrine/paracrine regulation of TNF- production by endogenously produced PGE2.
G prot, G-protein.
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endogenous anti-inflammatory response. Thus, PGE2/Egr-1
may form a critical axis involved in the modulation of the
immune (27) and inflammatory responses and may be essential
for the programming of cellular differentiation.
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